Best Traction Device for Peyronie's Disease

The best traction device for Peyronie's disease combines documented curvature evidence, calibrated tension, a verifiable regulatory identity, and a design comfortable enough to wear for the studied durations — backed by guarantee terms that survive their own fine print. In traction, the device you can actually wear is the device that works — an abandoned device treats nothing. This page helps you choose among the devices that deliver penile traction therapy, the non-surgical approach studied in clinical trials for the penile curvature of Peyronie's disease. A penile traction device is the tool that delivers that therapy, and the devices sold for this condition differ more in design, disclosure, and terms than marketing suggests. The evaluation sets the criteria, compares five candidates with every manufacturer claim dated and attributed, and closes with an honest recommendation a urologist could endorse.

Choosing a traction device for Peyronie's disease starts with what the device must physically do: hold a curved, healing shaft under controlled, sustained tension for months. Whether traction devices work for Peyronie's at all is answered in the next section; how the device class works against the condition is covered in the guide to the penile traction device for Peyronie's disease. This page owns the choice itself. The five criteria that separate a device that can help Peyronie's curvature from one that wastes months are defined below.

1. Peyronie's-relevant evidence

Choose a device — or a device class — that was studied for curvature, not one marketed on enlargement promises. The fibrous plaque of Peyronie's disease sits in the tunica albuginea, and curvature reduction is the outcome the clinical literature actually measured.

2. Calibrated, adjustable tension

A device that verifies and discloses its traction force in grams lets you and your clinician control the load on curved, healing tissue and progress it deliberately. Calibrated tension turns a gadget into a dosable therapy; a device that discloses no force figure leaves you guessing.

3. Wearability that sustains compliance

The studied protocols demand real wear time, day after day; an unwearable device fails by abandonment — the most common failure mode. Judge the comfort system, the fixation — silicone strap or glans chamber — and whether the fit sustains months of use. Design philosophies differ: counter-bending designs built for short daily sessions versus the multi-hour wear most of the class was studied at — a trade-off the comparison below examines.

4. Verifiable regulatory identity

Can you trust the regulatory badges on device websites? Only the ones you can check. A medical-grade device for a diagnosed condition should carry a regulatory identity that exists in a public record — an FDA-registered listing, a CE marking, a named legal manufacturer — rather than badge wording found nowhere else. The table below shows how sharply the five differ here.

5. Honest guarantee terms

Read the returns policy before the testimonials: the fine print is a buying signal. A money-back guarantee that survives its own conditions signals a manufacturer that expects the device to be kept; a no-returns or fee-laden policy tells you to be sure before you pay.

One rule sits above all five: device choice for a diagnosed condition belongs in a conversation with a urologist. You should bring the shortlist to the clinician who knows your phase and severity — the criteria find the candidates, and the device that fits your anatomy and your day is a medical decision.

Peer-reviewed clinical studies support penile traction therapy for the penile curvature of Peyronie's disease — but the evidence must be read by claim and by device. Pooled across devices and protocols, penile traction significantly reduced Peyronie's curvature (p=0.037) while leaving penile length statistically unchanged (p=0.53), the 2023 Almsaoud systematic review and meta-analysis in Transl Androl Urol (PMID 38106680) found. That meta-analysis is device-class evidence for curvature reduction — and for curvature only; reading it as a length study misreads it.

At the single-device level, honesty requires naming a competitor: the strongest published randomized controlled trial of a single traction device for Peyronie's disease was run on RestoreX. Curvature improved for 77% of the 110 men (randomized 3:1), 94% achieved increased length, and the six-month mean gain was 2.0–2.2 cm (0.8–0.9 in) — the Joseph trial of the RestoreX device, reported in J Sex Med (2020, PMID 33223425). Why does RestoreX come up in the research? Because the trial the rest of the field cites was run on the RestoreX device — a device its manufacturer states was developed in cooperation with Mayo Clinic (their wording, as of July 2026). A "best device" page that hides that is selling, not evaluating.

What the evidence does not contain matters as much: no head-to-head randomized controlled trial compares these traction devices against each other. The pooled result supports the therapy class; one device was studied in its own randomized trial; multiple peer-reviewed studies underpin the class protocols — so the buying decision falls back on the criteria: tension disclosure, wearability, regulatory identity, and terms. Traction is only one treatment among several for this condition; the full landscape of Peyronie's disease treatment options — including the medical and surgical routes this page deliberately does not cover — is mapped on the condition guide.

Four traction devices besides SizeGenetics are sold today for Peyronie's disease — RestoreX, Andropenis (sold for Peyronie's as Andropeyronie), the Quick Extender Pro Curvature edition, and PeniMaster PRO. The inclusion criterion is a Peyronie's-specific model, program, or published clinical positioning, available to buy today. Older devices once marketed for Peyronie's but no longer sold or supported are excluded. Every competitor value below is the manufacturer's own published claim, as of July 2026, attributed to its source — reported, not certified, so you can choose on facts.

RestoreX, from PathRight Medical, differs from the set by philosophy: its patented counter-bending mechanism is designed to work against the curve directly, and its program requires 30–60 minutes of daily use rather than multi-hour wear. It costs $525.00 at the Mayo Clinic Store as of July 2026, and its stated returns policy is that all sales are final — no returns, even unopened.

Andropenis, from Andromedical, sells its Peyronie's model as Andropeyronie — a rod-based extender with a stated tension spec of gradual 600 to 1,500 grams and a stated wear protocol of 4 or 9 hours a day (their two stated options, as of early July 2026). It is FDA-registered per andromedical.com's licenses page (as of early July 2026); its homepage advertises a money-back guarantee whose detailed conditions its official terms page does not publish.

Quick Extender Pro, from Innovatech Designs, sells a Curvature/Peyronies edition at $199.99 as of July 2026, per quickextenderpro.com. The company publishes no FDA or CE claim on its site and discloses no tension figure for the Curvature edition. Its 6-month money-back guarantee requires following their program for five months first and carries return fees, per their terms-of-use page.

PeniMaster PRO, from MSP Concept, discloses tension most precisely in this set: its gram-calibrated display shows traction force from 0 to roughly 1,250 g (their spec), and it fixes by a glans chamber rather than a silicone strap. It publishes no dedicated Peyronie's edition and no FDA or CE-class wording — its stated credential is "EN ISO 13485 certified" — and its terms state a 5-year warranty plus a 1-month money-back guarantee, at €389 for the complete set, as of July 2026, per penimaster.com.

SizeGenetics is an FDA-registered medical device, CE Marked, made by Danamedic ApS of Denmark — the category inventor since 1994, founded in 1988, with Dr. Jørn Ege Siana, plastic surgeon and co-inventor, behind the device. SizeGenetics' regulatory and medical-grade identity is stated precisely: registration is a status a buyer can verify, not proof of a curvature or length result — criterion four met by a named manufacturer with a documented identity.

On evidence, the honest case is already made above: SizeGenetics carries no device-specific Peyronie's randomized trial, and this page will not pretend otherwise. Its evidence base is the device-class traction literature — the pooled curvature result — and its argument is that it delivers that same therapy class. Criterion three is where that matters: the clinical protocols demand 4–6 hours per day over 3–6 months, and the device is built for exactly that multi-hour reality. Calibrated, adjustable tension and a multi-point comfort design target traction's true failure mode — abandonment — because comfort supports treatment compliance across months of use.

On terms, Danamedic discloses what the device is and backs the purchase with a money-back guarantee — in a field where the fine print is often the product. The full specification, package options, and current terms are on the product page for the SizeGenetics penile traction device. If you and your urologist decide traction fits your case, you should choose the device you will still be wearing in month four — where SizeGenetics makes its strongest case. Whether a device is the right treatment class at all is a broader question — for the treatment-wide comparison, and for your clinician.

Using a traction device for Peyronie's disease involves consistent daily use over months, not a quick fix: the studied protocols require real wear time — typically 4–6 hours per day — treatment spans 3–6 months, and the wearer adjusts the tension progressively as tissue adapts and the curvature responds. Phase matters too: a urologist supervises acute-phase use, while the chronic phase is when self-directed use is generally considered — the phase-by-phase protocol and safety rules live in their own guide. The studies' outcome language captures what consistency buys: improvements are described as maintained at 6–12-month follow-up, not as permanent. Because Peyronie's disease often brings penile shortening, length loss is part of what many men hope to address — the FAQ below scopes that answer. For therapy-level depth on this condition, see the guide to penile traction for Peyronie's disease; how owners rate these device choices is a separate lens — a reviews guide is coming.

Choosing the best traction device is one entry point into the broader Peyronie's disease topic. These pages cover the condition, the device class, the evidence, and the protocol.